Articles
Pharma marketing 2.0 – have we M.E.T yet?

Pharma marketing 2.0 – have we M.E.T yet?

Carrie L Carrier discusses the top three essential qualities that all pharma companies must have in order to achieve marketing excellence. Much has been written about pharmaceutical marketing's reluctance to fully embrace the new technologies taking...

Articles
Health Technology Assessment: how do we define best practices internationally?

Health Technology Assessment: how do we define best practice...

Alicia Granados of Genzyme speaks with pharmaphorum about how the health technology assessment space has evolved throughout her career and where she thinks it is heading. The growing importance of Health Technology Assessments (HTAs) in reimbursement decision-making cannot be...

Articles
Pharma news highlights: Eli Lilly, Abbott and more

Pharma news highlights: Eli Lilly, Abbott and more

Ed Silverman shares his news highlights from the past few weeks, which includes an incorrect CV, a lawsuit over male breasts and an alleged over-hyped clinical study. The past month may have marked the end of summer, but there was no shortage of interesting affairs in...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D